Sound Income Strategies LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 27.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,237 shares of the company’s stock after acquiring an additional 2,642 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of Sound Income Strategies LLC’s holdings, making the stock its 20th biggest holding. Sound Income Strategies LLC’s holdings in Johnson & Johnson were worth $1,704,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of JNJ. Billeaud Capital Management Inc. increased its position in shares of Johnson & Johnson by 0.4% in the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock worth $6,130,000 after acquiring an additional 169 shares in the last quarter. Meeder Asset Management Inc. grew its stake in shares of Johnson & Johnson by 29.1% during the fourth quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock worth $12,679,000 after purchasing an additional 22,157 shares in the last quarter. Freestone Capital Holdings LLC grew its stake in shares of Johnson & Johnson by 8.3% during the fourth quarter. Freestone Capital Holdings LLC now owns 25,526 shares of the company’s stock worth $3,294,000 after purchasing an additional 1,954 shares in the last quarter. Lcnb Corp grew its stake in shares of Johnson & Johnson by 2.8% during the fourth quarter. Lcnb Corp now owns 15,279 shares of the company’s stock worth $1,972,000 after purchasing an additional 410 shares in the last quarter. Finally, Smart Money Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $224,000. 66.82% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on the stock. BMO Capital Markets boosted their target price on shares of Johnson & Johnson from $154.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Raymond James dropped their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Wells Fargo & Co reissued an “outperform” rating and issued a $157.00 target price (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Finally, Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $148.56.
Shares of Johnson & Johnson stock traded down $1.38 on Wednesday, reaching $129.39. The stock had a trading volume of 1,576,037 shares, compared to its average volume of 7,791,626. The business has a 50-day moving average price of $135.95. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a market capitalization of $345.92 billion, a PE ratio of 15.82, a P/E/G ratio of 2.22 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.10 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.94%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is quantitative easing?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.